scholarly journals Cost-Effectiveness Evaluation of Data from the Evidence (Evidence of Interferon Dose-Response: European North American Comparative Efficacy) Study

2014 ◽  
Vol 17 (7) ◽  
pp. A397
Author(s):  
A.L. Phillips ◽  
N.C. Edwards ◽  
J.C. Locklear
2004 ◽  
Vol 6 (1) ◽  
pp. 23-25
Author(s):  
Edward Monaghan ◽  
Marylou Basile ◽  
Olympia Hadjimichael ◽  
Timothy L. Vollmer ◽  
Gordon S. Francis

This paper describes the methods used to recruit patients for the EVIDENCE (EVidence for Interferon Dose-Effect: European-North American Comparative Efficacy) study, and the results of that recruitment. The majority of enrolled patients came from the investigators' clinic populations, with an additional 30% entering the study as a result of specific recruitment efforts. Local efforts, including referrals from colleagues, postings on bulletin boards, contacts with local Multiple Sclerosis Society chapters and newspaper advertisements, were the most successful recruitment tools. Mass mailings to local neurologists, referrals from a national multiple sclerosis registry, Web sites, and radio or television spots were less effective in recruiting eligible patients.


1996 ◽  
Author(s):  
Bradford D. Gessner ◽  
Steven M. Teutsch ◽  
Phaedra A. Shaffer

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Chun-Yi Lu ◽  
Ching-Hu Chung ◽  
Li-Min Huang ◽  
Eliza Kruger ◽  
Seng-Chuen Tan ◽  
...  

An amendment to this paper has been published and can be accessed via the original article.


2012 ◽  
Vol 23 ◽  
pp. ii29
Author(s):  
R. Rouzier ◽  
E. Chereau ◽  
E. Laas ◽  
A. Genin ◽  
S. Bendifallah ◽  
...  

2015 ◽  
Vol 39 (1-3) ◽  
pp. 174-180 ◽  
Author(s):  
Vincenzo Panichi ◽  
Alberto Rosati ◽  
Adriana Di Giorgio ◽  
Alessia Scatena ◽  
Roberto Bigazzi ◽  
...  

Background: A pharmacoeconomic analysis of the RISCAVID database aimed at assessing the cost effectiveness of phosphate binders in preventing CV mortality and morbidity over 7 years was performed. Methods: Morbid or fatal events occurring in 750 chronic HD patients were recorded. Statistical analysis evaluated the distribution of variables and the effect of sevelamer on survival. A cost-effectiveness evaluation was performed using a probabilistic model based on a Markov chain. Results: Multivariate analysis showed that treatment with sevelamer was associated with a reduced stroke incidence by 52% (p = 0.04) and reduced levels of C-reactive protein (p < 0.01). Cost-effectiveness evaluation evidenced a 33% decrease in hospital-days for patients treated with sevelamer, with and without comorbidities compared to patients undergoing calcium binders treatment. Conclusion: Treatment with sevelamer was associated with a reduced risk of stroke in HD patients, with a clear saving on disease-related costs for the Italian National Healthcare System.


Sign in / Sign up

Export Citation Format

Share Document